We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Method Developed to Estimate LDL Particle Size

By LabMedica International staff writers
Posted on 01 Apr 2020
Print article
Image: The high throughput immunochemistry cobas e 801 module (Photo courtesy of Roche Diagnostics).
Image: The high throughput immunochemistry cobas e 801 module (Photo courtesy of Roche Diagnostics).
Premature atherosclerotic disease commonly occurs in individuals with atherogenic dyslipidemia who share a phenotype characterized by centripetal obesity, insulin resistance, and physical inactivity. Cardiovascular diseases (CVD) are the leading cause of mortality in the Western World being subclinical atherosclerosis the triggering factor for most of these events.

The reduction in the incidence of cardiovascular events requires the early detection of cardiovascular risk factors (CVRFs), such as low‐density lipoprotein cholesterol (LDL‐C) concentration, nowadays the most important therapeutic target. However, it has been demonstrated that lowering LDL‐C concentration is not enough to prevent all ischemic events even in patients without CVRFs.

Medical scientists at the Bellvitge University Hospital (Barcelona, Spain) and their colleagues included in their study 85 patients who were 19 to 75‐year‐old male non‐smokers. Each patient had their biochemical profiles assessed. A complete lipid profile for each patient was also attained including plasma concentrations of cholesterol, very low‐density lipoprotein cholesterol (VLDL‐C), intermediate‐density lipoprotein cholesterol (IDL‐C), triglycerides (Tg), LDL‐C, high‐density lipoprotein cholesterol (HDL‐C), apolipoprotein A (ApoA‐I), apolipoprotein B (ApoB), apolipoprotein E (ApoE), apolipoprotein CIII (ApoCIII), and lipoprotein A (LPA). In addition, atherogenic indices were calculated using the following formula: IA = LDL‐C/HDL‐C. LDL size (LDL‐Z) and LDL-particles (LDL‐P) and small dense LDL (sdLDL‐C) were also measured.

Supernatant HDL‐C and total cholesterol were measured using a Cobas 8000 modular analyzer (Roche Diagnostics, Risch-Rotkreuz, Switzerland). Cholesterol concentration was determined enzymatically using cholesterol esterase and cholesterol oxidase in the Roche diagnostics Cobas 701. Since supernatant only contained HDL and sdLDL particles, the sdLDL‐C was calculated by subtracting the HDL‐C from the total cholesterol concentration. The nuclear magnetic resonance (NMR) analyses were carried out with the Vantera analyzer (LipoScience, Inc, Morrisville, NC, USA).

The investigators reported that regarding the relation between sdLDL‐C concentration variation and LDL‐Z, they found that an increase in the diameter of LDL particles implies a decrease in sdLDL‐C concentration. Importantly, taking into account the multivariate regression, an increment of 1 nm in LDL size leads to a 126 nmol/L reduction in sdLDL‐C concentration. As a consequence, smaller LDL particles contain a higher concentration of cholesterol. Due to its composition, smaller LDL particles would support the formation and progression of the atheroma plaques in higher degree than larger ones.

The authors concluded that the association between sdLDL‐C, LDL‐Z, and LDL‐P was clear. From a large number of variables, especially LDL‐Z and apoB influence on sdLDL‐C. The results showed that the smaller the LDL size, the higher their cholesterol concentration. Therefore, sdLDL‐C determination by using this easy method would be useful to risk stratification and to uncover cardiovascular residual risk. The study was published on March 21, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Bellvitge University Hospital
Roche Diagnostics
LipoScience


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.